Park JO - Search Results

1

Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.

Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park SH, Park JO, Kim WS, Kang WK, Lee HM, Choi HY, Lim H. Hong JY, et al. Among authors: park mj, park sh, park jo. Med Oncol. 2009;26(2):186-92. doi: 10.1007/s12032-008-9106-7. Epub 2008 Nov 6. Med Oncol. 2009. PMID: 18988001

2

Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer.

Kim K, Nam E, Lee NS, Lee HR, Lee JY, Lee HR, Park SH, Oh SY, Kim JH, Song SY, Park JO, Kim WS, Jung CW, Im YH, Lee MH, Lee WY, Chun H, Park CH, Park K, Kang WK. Kim K, et al. Among authors: park sh, park jo, park ch, park k. Am J Clin Oncol. 2002 Aug;25(4):354-7. doi: 10.1097/00000421-200208000-00007. Am J Clin Oncol. 2002. PMID: 12151964 Clinical Trial.

3

Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis.

Park WH, Jung CW, Park JO, Kim K, Kim WS, Im YH, Lee MH, Kang WK, Park K. Park WH, et al. Among authors: park jo, park k. Int J Oncol. 2003 Apr;22(4):855-60. Int J Oncol. 2003. PMID: 12632079

4

Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis.

Park WH, Jung CW, Park JO, Kim K, Kim WS, Im YH, Lee MH, Kang WK, Park K. Park WH, et al. Among authors: park jo, park k. Int J Oncol. 2003 May;22(5):1129-34. Int J Oncol. 2003. PMID: 12684681

5

A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.

Park J, Ahn YC, Kim H, Lee SH, Park SH, Lee KE, Lim DH, Park J, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. Park J, et al. Lung Cancer. 2003 Nov;42(2):227-35. doi: 10.1016/s0169-5002(03)00282-4. Lung Cancer. 2003. PMID: 14568691 Clinical Trial.

6

Promoter methylation and down-regulation of DAPK is associated with gastric atrophy.

Kim WS, Son HJ, Park JO, Song SY, Park C. Kim WS, et al. Among authors: park c, park jo. Int J Mol Med. 2003 Dec;12(6):827-30. Int J Mol Med. 2003. PMID: 14612952

7

Measuring response in solid tumors: comparison of RECIST and WHO response criteria.

Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K. Park JO, et al. Among authors: park ys, park k. Jpn J Clin Oncol. 2003 Oct;33(10):533-7. doi: 10.1093/jjco/hyg093. Jpn J Clin Oncol. 2003. PMID: 14623923

8

Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer.

Lee SH, Ahn YC, Kim HJ, Lim DH, Lee SI, Nam E, Park SH, Park J, Lee KE, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park K. Lee SH, et al. Among authors: park sh, park jo, park k, park j. Jpn J Clin Oncol. 2003 Dec;33(12):620-5. doi: 10.1093/jjco/hyg115. Jpn J Clin Oncol. 2003. PMID: 14769839 Clinical Trial.

9

The outcomes of hypertransfusion in major ABO incompatible allogeneic stem sell transplantation.

Park SH, Lee MH, Lee SH, Lee KE, Park J, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K, Kim SW, Lee KH, Lee JH. Park SH, et al. Among authors: park jo, park k, park j. J Korean Med Sci. 2004 Feb;19(1):79-82. doi: 10.3346/jkms.2004.19.1.79. J Korean Med Sci. 2004. PMID: 14966346 Free PMC article.

10

Tuberculosis in hematopoietic stem cell transplant recipients in Korea.

Lee J, Lee MH, Kim WS, Kim K, Park SH, Lee SH, Lee KE, Park J, Park JO, Jung CW, Im YH, Kang WK, Park K. Lee J, et al. Among authors: park sh, park jo, park k, park j. Int J Hematol. 2004 Feb;79(2):185-8. doi: 10.1532/ijh97.a10219. Int J Hematol. 2004. PMID: 15005349

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

902 results

Search Page

Filters